It is recommended to begin therapy with intranasal administration of the preparation IMMUNOVAK-VP-4® lyophilizate for the preparation of a solution for intranasal administration and a solution for oral administration according to the scheme indicated in the instructions.
Later they switch to subcutaneous administration of this drug.
In the ampoule with the drug, just before use, 0.5 ml of solvent is added using a syringe (sodium chloride solvent for the preparation of medicinal forms for injection 0.9%) temperatures of 18-25 ° C. The dissolution time should not exceed 2 min. Dissolved drug is not subject to storage.
The drug is injected with a syringe into the area of the lower angle of the scapula according to the scheme.
Scheme of drug application
| № procedures | Interval between in theMr.countries | Dose | Method introduction of | Note |
| 1 |
| 0.1 ml | Subcutaneously in the area of the lower angle of the scapula | Alternately change the side of the introduction |
| 2 | 3-5 days | 0.2 ml |
| 3 | 3-5 days | 0.2 ml |
| 4 | 3-5 days | 0.2 ml |
| 5 | 3-5 days | 0,2 ml * |
* with insufficient effectif there is no response to 4-5 subcutaneous administration, the course of administration of the drug may be extended to 8 injections in a dose of 0.2 ml at intervals of 3-5 days if the patient's temperature does not exceed 37.5 ° C.
When introducing the next dose, it is necessary to take into account the intensity of the reaction to the previous injection.
If the body temperature rises by more than 0.5 ° C with subsequent administration, the dose of the drug is not increased.
At insufficiently expressed effect at immunotherapy of relapses of simple genital and nasolabial herpes, as well as acute and chronic inflammatory diseases of the skin
an increase in the dose to 0.3-0.4 ml (no more), it is possible for individuals who had no local and general reactions for a dose of 0.2 ml.
The maximum possible number of injections is 8.
Conducting repeated courses of immunotherapy - no earlier than 1 year if there are indications.